| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 20.9 | 37.9 | 13.6 |
| Total income | 20.9 | 37.9 | 13.6 |
| Profit before exceptional items & tax | 1.5 | 0.7 | 0.2 |
| Profit before tax | 1.5 | 0.7 | 0.2 |
| Net profit | 1.1 | 0.5 | 0.1 |
| Operating margin | 7.2% | 1.8% | 1.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1000.00% |
|---|---|
| Net profit, quarter on quarter | +120.00% |
| Revenue, year on year | +53.70% |
BSE results filing, NSE: CONCORD. Figures extracted from the filing.
Concord Drugs Ltd: key numbers
- Share price
- ₹78.33
- Market cap
- ₹103.2 Cr
- Revenue (annual)
- ₹78.74 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 50.3×Sector 50.4×
- Promoter holding
- 45.08%-9.31% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Drugs Ltd
All →Concord Drugs Other Announcement
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Annual Report
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs Annual General Meeting
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.
Concord Drugs Q4 FY26 Results: Net Profit ₹0.5 Cr, Up 150.0% QoQ
Concord Drugs Ltd reported revenue from operations of ₹37.9 Cr (+264.4% YoY) and net profit of ₹0.5 Cr for Q4 FY26.
- Key figure
- Net profit ₹0.5 Cr